baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

HSBC TUR.WAR.OP.END. RGO/ DE000HS37RG5 /

14/06/2024 21:36:05	Chg.+1.020	Bid21:59:56	Ask21:59:56	Underlying	Strike price	Expiration date	Option type
17.820EUR	+6.07%	17.810 Bid Size: 10,000	18.110 Ask Size: 10,000	Regeneron Pharmaceut...	848.5763 USD	31/12/2078	Call

GlobeNewswire 13/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 11/06 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...

GlobeNewswire 05/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 04/06 Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 03/06 FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroG...

GlobeNewswire 31/05 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 31/05 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewswire 31/05 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 31/05 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...

GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 28/05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 23/05 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...

GlobeNewswire 22/05 Invivyd Elects Two New Independent Members to its Board of Directors

GlobeNewswire 21/05 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire 20/05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 20/05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 20/05 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 20/05 Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...

GlobeNewswire 17/05 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...

GlobeNewswire 14/05 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...

GlobeNewswire 14/05 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

GlobeNewswire 13/05 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 10/05 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 09/05 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...

GlobeNewswire 08/05 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

HSBC TUR.WAR.OP.END. RGO/ DE000HS37RG5 /

If you wish to receive reply to your feedback, please provide your email address.